-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor’s note iNature is China’s largest academic official account.
It is jointly created by the doctoral team of Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature Talent Official Account is now launched, focusing on talent recruitment, academic progress, scientific research information, and interested parties.
Long press or scan the QR code below to follow us
.
iNature extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a highly aggressive subtype of non-Hodgkin’s lymphoma (NHL) with a high incidence in Asia and Latin America
.
In China, ENKTL accounts for 6.
6% of all NHL and 28.
1% of peripheral T lymphoma (PTCL)
.
The 5-year overall survival (OS) of ENKTL patients is 40-50%
.
Due to the high expression of multidrug resistant P-glycoprotein, ENKTL does not respond well to traditional anthracycline chemotherapy
.
This study (ORIENT-4) aims to evaluate Sintilimab (Sintilimab, a humanized anti-PD-1 antibody) in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL) In the efficacy and safety
.
On October 27, 2021, Li Jianyong and Fan Lei of Nanjing Medical University published an online newsletter titled "Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm" in Signal Transduction and Targeted Therapy (IF=18.
19).
, phase 2 trial (ORIENT-4)" research paper, this study is a multi-center, single-arm, phase 2 clinical trial (NCT03228836)
.
Patients with r/r ENKTL who failed at least one asparaginase-based treatment regimen were enrolled and received 200 mg Sintilizumab intravenously every 3 weeks for up to 24 months
.
The primary endpoint is the objective response rate (ORR) based on Lugano's 2014 criteria
.
28 r/r ENKTL patients were enrolled from August 31, 2017 to February 7, 2018
.
21 patients (75.
0%, 95% CI: 55.
1-89.
3%) achieved objective remission
.
The median follow-up was 30.
4 months, and the median overall survival (OS) was not reached
.
The 24-month OS rate was 78.
6% (95% CI, 58.
4-89.
8%)
.
Most treatment-related adverse events (TRAE) were grade 1-2 (71.
4%), and the most common TRAE was a decrease in lymphocyte count (42.
9%)
.
Seven (25.
0%) patients had serious adverse events (SAE), and no patients died of adverse events
.
Sintilimab is effective and well tolerated in patients with r/r ENKTL, and may become a new treatment method to control ENKTL in patients
.
Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a highly aggressive subtype of non-Hodgkin's lymphoma (NHL) with a high incidence in Asia and Latin America
.
In China, ENKTL accounts for 6.
6% of all NHL and 28.
1% of peripheral T lymphoma (PTCL)
.
The 5-year overall survival (OS) of ENKTL patients is 40-50%
.
Due to the high expression of multidrug resistant P-glycoprotein, ENKTL does not respond well to traditional anthracycline chemotherapy
.
The asparaginase-based regimen is effective for ENKTL, with an objective response rate (ORR) of 67–79% and a complete response rate (CR) of 45–61%
.
Patients who fail to treat asparaginase have a limited median survival time of <6 months
.
Epstein–Barr virus (EBV) infection is an important etiology and prognostic factor of ENKTL
.
Overexpression of PD-L1 induced by EBV infection is a potential mechanism for ENKTL to avoid immune surveillance.
Anti-PD-1 antibody/refractory (r/r) ENKTL in patients with relapse has shown potential efficacy
.
Anti-PD-1 monoclonal antibody (mAb) can rescue T cell viability suppressed by EBV-positive diffuse large B-cell lymphoma
.
Two retrospective studies with limited sample sizes showed that pembrolizumab is active in r/r ENKTL, with ORRs of 100% (n = 7) and 57.
1% (n = 7), respectively
.
Two case reports also demonstrated the efficacy of anti-PD-1 mAb in r/r ENKTL after asparaginase-based treatment
.
Recently, a study reported the effectiveness and safety of PD-L1 antibody-avelumab as a single-agent treatment of r/r ENKTL, showing an ORR of 38% and a CR rate of 24% in 21 patients
.
However, there is little clinical evidence regarding the anti-tumor activity of PD-1 inhibitors in ENKTL patients
.
Sintilimab (sintilimab) is a recombinant humanized anti-PD-1 mAb that can bind to human PD-1
.
According to preclinical data, compared with pembrolizumab or nivolumab, sintilimab has a different binding site and may have a higher affinity for PD-1
.
Sintilimab has proven to have clinical benefits in various cancers
.
This prospective phase 2 study aims to evaluate the efficacy and safety of sintilimab on r/r ENKTL
.
The study is a multi-center, single-arm, phase 2 clinical trial (NCT03228836)
.
Patients with r/r ENKTL who failed at least one asparaginase-based treatment regimen were enrolled and received 200 mg Sintilizumab intravenously every 3 weeks for up to 24 months
.
The primary endpoint is the objective response rate (ORR) based on Lugano's 2014 criteria
.
28 r/r ENKTL patients were enrolled from August 31, 2017 to February 7, 2018
.
21 patients (75.
0%, 95% CI: 55.
1-89.
3%) achieved objective remission
.
The median follow-up was 30.
4 months, and the median overall survival (OS) was not reached
.
The 24-month OS rate was 78.
6% (95% CI, 58.
4-89.
8%)
.
Most treatment-related adverse events (TRAE) were grade 1-2 (71.
4%), and the most common TRAE was a decrease in lymphocyte count (42.
9%)
.
Seven (25.
0%) patients had serious adverse events (SAE), and no patients died of adverse events
.
Sintilimab is effective and well tolerated in patients with r/r ENKTL, and may become a new treatment method to control ENKTL in patients
.
Reference message: https://
It is jointly created by the doctoral team of Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature Talent Official Account is now launched, focusing on talent recruitment, academic progress, scientific research information, and interested parties.
Long press or scan the QR code below to follow us
.
iNature extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a highly aggressive subtype of non-Hodgkin’s lymphoma (NHL) with a high incidence in Asia and Latin America
.
In China, ENKTL accounts for 6.
6% of all NHL and 28.
1% of peripheral T lymphoma (PTCL)
.
The 5-year overall survival (OS) of ENKTL patients is 40-50%
.
Due to the high expression of multidrug resistant P-glycoprotein, ENKTL does not respond well to traditional anthracycline chemotherapy
.
This study (ORIENT-4) aims to evaluate Sintilimab (Sintilimab, a humanized anti-PD-1 antibody) in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL) In the efficacy and safety
.
On October 27, 2021, Li Jianyong and Fan Lei of Nanjing Medical University published an online newsletter titled "Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm" in Signal Transduction and Targeted Therapy (IF=18.
19).
, phase 2 trial (ORIENT-4)" research paper, this study is a multi-center, single-arm, phase 2 clinical trial (NCT03228836)
.
Patients with r/r ENKTL who failed at least one asparaginase-based treatment regimen were enrolled and received 200 mg Sintilizumab intravenously every 3 weeks for up to 24 months
.
The primary endpoint is the objective response rate (ORR) based on Lugano's 2014 criteria
.
28 r/r ENKTL patients were enrolled from August 31, 2017 to February 7, 2018
.
21 patients (75.
0%, 95% CI: 55.
1-89.
3%) achieved objective remission
.
The median follow-up was 30.
4 months, and the median overall survival (OS) was not reached
.
The 24-month OS rate was 78.
6% (95% CI, 58.
4-89.
8%)
.
Most treatment-related adverse events (TRAE) were grade 1-2 (71.
4%), and the most common TRAE was a decrease in lymphocyte count (42.
9%)
.
Seven (25.
0%) patients had serious adverse events (SAE), and no patients died of adverse events
.
Sintilimab is effective and well tolerated in patients with r/r ENKTL, and may become a new treatment method to control ENKTL in patients
.
Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a highly aggressive subtype of non-Hodgkin's lymphoma (NHL) with a high incidence in Asia and Latin America
.
In China, ENKTL accounts for 6.
6% of all NHL and 28.
1% of peripheral T lymphoma (PTCL)
.
The 5-year overall survival (OS) of ENKTL patients is 40-50%
.
Due to the high expression of multidrug resistant P-glycoprotein, ENKTL does not respond well to traditional anthracycline chemotherapy
.
The asparaginase-based regimen is effective for ENKTL, with an objective response rate (ORR) of 67–79% and a complete response rate (CR) of 45–61%
.
Patients who fail to treat asparaginase have a limited median survival time of <6 months
.
Epstein–Barr virus (EBV) infection is an important etiology and prognostic factor of ENKTL
.
Overexpression of PD-L1 induced by EBV infection is a potential mechanism for ENKTL to avoid immune surveillance.
Anti-PD-1 antibody/refractory (r/r) ENKTL in patients with relapse has shown potential efficacy
.
Anti-PD-1 monoclonal antibody (mAb) can rescue T cell viability suppressed by EBV-positive diffuse large B-cell lymphoma
.
Two retrospective studies with limited sample sizes showed that pembrolizumab is active in r/r ENKTL, with ORRs of 100% (n = 7) and 57.
1% (n = 7), respectively
.
Two case reports also demonstrated the efficacy of anti-PD-1 mAb in r/r ENKTL after asparaginase-based treatment
.
Recently, a study reported the effectiveness and safety of PD-L1 antibody-avelumab as a single-agent treatment of r/r ENKTL, showing an ORR of 38% and a CR rate of 24% in 21 patients
.
However, there is little clinical evidence regarding the anti-tumor activity of PD-1 inhibitors in ENKTL patients
.
Sintilimab (sintilimab) is a recombinant humanized anti-PD-1 mAb that can bind to human PD-1
.
According to preclinical data, compared with pembrolizumab or nivolumab, sintilimab has a different binding site and may have a higher affinity for PD-1
.
Sintilimab has proven to have clinical benefits in various cancers
.
This prospective phase 2 study aims to evaluate the efficacy and safety of sintilimab on r/r ENKTL
.
The study is a multi-center, single-arm, phase 2 clinical trial (NCT03228836)
.
Patients with r/r ENKTL who failed at least one asparaginase-based treatment regimen were enrolled and received 200 mg Sintilizumab intravenously every 3 weeks for up to 24 months
.
The primary endpoint is the objective response rate (ORR) based on Lugano's 2014 criteria
.
28 r/r ENKTL patients were enrolled from August 31, 2017 to February 7, 2018
.
21 patients (75.
0%, 95% CI: 55.
1-89.
3%) achieved objective remission
.
The median follow-up was 30.
4 months, and the median overall survival (OS) was not reached
.
The 24-month OS rate was 78.
6% (95% CI, 58.
4-89.
8%)
.
Most treatment-related adverse events (TRAE) were grade 1-2 (71.
4%), and the most common TRAE was a decrease in lymphocyte count (42.
9%)
.
Seven (25.
0%) patients had serious adverse events (SAE), and no patients died of adverse events
.
Sintilimab is effective and well tolerated in patients with r/r ENKTL, and may become a new treatment method to control ENKTL in patients
.
Reference message: https://
